Emerald Mutual Fund Advisers Trust Boosts Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Emerald Mutual Fund Advisers Trust increased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 530,456 shares of the specialty pharmaceutical company’s stock after buying an additional 19,255 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 1.62% of Collegium Pharmaceutical worth $17,081,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its stake in Collegium Pharmaceutical by 26.9% during the fourth quarter. Russell Investments Group Ltd. now owns 32,073 shares of the specialty pharmaceutical company’s stock worth $987,000 after acquiring an additional 6,796 shares during the last quarter. National Bank of Canada FI acquired a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth about $1,855,000. Principal Securities Inc. purchased a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $40,000. Versor Investments LP lifted its position in Collegium Pharmaceutical by 14.2% in the fourth quarter. Versor Investments LP now owns 10,579 shares of the specialty pharmaceutical company’s stock valued at $326,000 after buying an additional 1,316 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Collegium Pharmaceutical by 119.6% in the fourth quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock valued at $4,511,000 after buying an additional 79,823 shares during the last quarter.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of research analyst reports. HC Wainwright boosted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 31st. Truist Financial upped their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and increased their target price for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $37.19 on Friday. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 15.50 and a beta of 0.94. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical, Inc. has a 52 week low of $20.95 and a 52 week high of $40.95. The company has a fifty day simple moving average of $35.01 and a two-hundred day simple moving average of $35.35.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. Collegium Pharmaceutical’s revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.13 EPS. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.